Twenty-three human T lymphotropic virus type I (HTLV-I) seroconverters were identified among 1120 HTLV-I-seronegative adults followed up for 11 years in an area of Japan endemic for HTLV-I. The geometric mean titer of anti-HTLV-I was 1:453 in the first year after seroconversion; the titer of each subject did not change significantly during 2-10 years of followup. HTLV-I proviral DNA load was quantified in 15 seroconverters, and a broad range of levels was observed-from !10 to 11000 copies/10 5 peripheral blood mononuclear cells. However, there was no obvious change in HTLV-I proviral DNA load over several years within individual subjects. Therefore, both proviral DNA load and humoral response in adult HTLV-I seroconverters were shown to stabilize within a few years after initial infection. In addition, 1 subject tested positive for HTLV-I proviral DNA before antibody seroconversion, which suggests the existence of a window period in community-acquired infection.
were seen during follow-up. Most seroconversions occurred in subjects married to an anti-HTLV-I-positive partner [9] . High anti-HTLV-I titer and presence of anti-Tax in the infected spouse have been associated with the risk of seroconversion in the partner [9, [11] [12] [13] . In the early antibody profile, we found that both anti-envelope protein gp46 and anti-core proteins p24 and p19 are detectable at the time of seroconversion [14] . However, previous studies did not evaluate time sequence changes in antibody responses and HTLV-I proviral DNA load after seroconversion.
In the present study (after 11 years of follow-up), we analyzed antibody response and HTLV-I proviral DNA load in 23 MCS seroconverters. We also investigated the detection of HTLV-I DNA before anti-HTLV-I seroconversion.
Subjects and Methods
Study population. The MCS is composed of residents from 2 small villages in Miyazaki Prefecture, Japan. These persons attend free government-sponsored health examinations and are asked to participate in the study. These annual health screens are targeted primarily to persons у40 years old. Blood specimens are collected at each screening. The study population is highly endemic for HTLV-I infection, with a baseline enrollment prevalence of ∼26%.
Sample preparation. Plasma samples were obtained and stored at Ϫ30ЊC until use. When possible, peripheral blood mononuclear cells (PBMC) also were isolated from the peripheral blood of the subjects by ficoll-paque gradient centrifugation. The isolated cells were washed with PBS and immediately were stored at Ϫ80ЊC. Chromosomal DNA was isolated by SDS-protease K digestion of the cells at 56ЊC, followed by phenol-chloroform extraction and ethanol precipitation of DNA. . Nos. at top of panels indicate year of sample collection (year 0, reference year for last seronegative sample). A, Immunoblot analysis of anti-HTLV-I for samples from different screens before and after seroconversion. N, negative control sample from test kit; P, positive control sample from test kit that showed reactivity to HTLV-I core proteins (p53, p24, and p19) and envelope protein (gp46). B, Detection of HTLV-I pX sequence in genomic DNA from peripheral blood mononuclear cells, using nested polymerase chain reaction. N, negative control genomic DNA from MOLT-4 cells; P, positive control genomic DNA from HuT 102 cells.
Serologic study. The presence of anti-HTLV-I antibody in the plasma samples was tested by using particle agglutination assay (PAA [Serodia-HTLV]; Fuji Rebio) and was confirmed by immunoblot assay (Problot-HTLV; Fuji Rebio). Positivity was judged according to criteria provided by the manufacturer. End-point dilution titers also were determined by PAA on the basis of 2-fold dilutions.
Detection and quantitation of HTLV-I proviral DNA loads. HTLV-I proviral DNA loads in PBMC were quantitated by AmpliSensor assay (Biotronics) [15] . This assay, a polymerase chain reaction (PCR)-based method, measures the target sequence quantitatively. All procedures were done according to the manufacturer's protocol, except with a slight modification, as described below. In brief, we used 5 mL of genomic DNA (100 ng/mL) as the template for the first asymmetric PCR, which was followed by seminested amplification, using labeled AmpliSensor primers. Data were analyzed by the AmpliSensor analysis program that was provided by the manufacturer. To ensure the accuracy of the quantitation of HTLV-I proviral DNA loads, we used the 2 primer pairs for the HTLV-I gag sequence described by Etoh et al. [16] ; for the HTLV-I pol sequence, we used the AcuGen HTLV-I quantitation test (Biotronics). As positive controls, we used the genomic DNA of PBMC from patients with acute ATL, who had a high number of leukemic cells in peripheral blood. The integration of 1 complete HTLV-I provirus per cell in the leukemic cells was confirmed by using Southern blot assay [16] . Different concentrations (0.01%, 0.1%, 1%, 10%, and 100%) of the genomic DNA from the ATL patients was mixed with the genomic DNA of HTLV-I-negative healthy volunteers (10, 100, 1000, 10,000, and 100,000 copies/10 5 PBMC, respectively) and was used as the standard for quantitation. The results of the quantitation of HTLV-I proviral DNA loads are shown as the number of copies per 10 5 PBMC. The AmpliSensor assay allowed for the detection of HTLV-I provirus as low as 10 copies/10 5 PBMC (data not shown).
For the detection of HTLV-I proviral DNA load in the samples with low copy numbers (i.e., !10 copies/10 5 PBMC by AmpliSensor assay), especially those collected before anti-HTLV-I seroconversion, we used a highly sensitive nested PCR, as described by Matsumoto et al. [17] . In brief, we amplified 1 mg of genomic DNA by using internal and external primer pairs designed from the pX region of HTLV-I. This nested PCR allowed for the detection of 1 or 2 copies of target sequence in the reaction (data not shown).
Statistical analysis. Geometric mean titers were calculated for anti-HTLV-I levels detected in the first antibody-positive sample. The change in titer over time was assessed by calculating the slope of the titer dilution for each seroconverter and by evaluating whether the overall average slope differed significantly from zero (i.e., no change in titer dilution over time) by using the Student's t test. The year of the last antibody-negative sample was considered the reference time point, with the year of the subsequent antibodypositive samples determined accordingly (e.g., year 1, antibodypositive sample collected 1 year after the previous seronegative NOTE. Blank space indicates missing data because of nonattendance at annual health examination. Data are for year (Y) of screen from which samples were tested. All case subjects were negative at Y0 (not shown).
sample; year 2, antibody-positive sample collected 2 years after the previous seronegative sample).
Results
From November 1984 through April 1996, anti-HTLV-I seroconversion was assessed among 1120 MCS subjects who initially tested negative for HTLV-I. After 12 rounds of annual screening with PAA and р11 years of follow-up (table 1), 23 seroconversions were identified. These seroconversions were confirmed by using immunoblot assay of у2 samples from different years before and after the seroconversion. Four men and 19 women seroconverted; median age at seroconversion was 58 years. Samples from 18 spouses of 23 seroconverters were available for testing for anti-HTLV-I. Of these 18 samples, 16 (90%) were positive, and 2 were negative (table 1). Two of the 23 seroconverters had a history of blood transfusion у8 years before the seroconversion.
Seventeen seroconverters (case subjects 1, 2, 5-10, 13, 15-17, and 19-23) participated in a health screen near the time of the HTLV-I seroconversion (i.e., 1 year between the last seronegative and first seropositive sample). Thus, it was possible to analyze their plasma samples in the initial year of seroconversion. Figure 1 shows a representative immunoblot profile for 1 seroconverter (case subject 19). For this case subject, no reactivity to any of the examined HTLV-I core (p53, p24, and p19) and envelope proteins (gp46) was seen in the samples obtained from the screens 8 years before seroconversion. Reactivity to all the examined HTLV-I proteins was seen in the initial year of seroconversion. Table 2 shows changes in anti-HTLV-I titer over time (after seroconversion) for each of the 23 seroconverters. The geometric mean titer was 1:453 for the 17 seroconverters whose antibody positivity first occurred within 1 year of the previously seronegative sample; 14 had a moderately high antibody titer (у1:512). In the other 6 seroconverters (case subjects 3, 4, 11, 12, 14, and 18), anti-HTLV-I seroconversion was detected 2-3 years after a previously negative sample. When the sequential change of anti-HTLV-I titers was examined for each of the 23 seroconverters, the average titer increased slightly over time during the observation period; however, this change was not statistically significant ( ). No seroconverter lost anti-P p .072 HTLV-I during the follow-up period.
Quantitation of HTLV-I proviral DNA load was done for 15 seroconverters with available PBMC by using primers for the HTLV-I gag or pol sequence (table 3). For 8 seroconverters (case subjects 2, 3, 9, 13-15, 18, and 22), the HTLV-I proviral DNA loads were measured by using the primers for both the gag and pol sequences on the same sample, and the HTLV-I proviral DNA loads that were measured varied only 2-3-fold between these primers, which suggests the relatively consistent quantitation of HTLV-I proviral DNA load by the methods used in the present study. When the HTLV-I proviral DNA loads in the initial year of seroconversion were compared among the seroconverters, there was a wide range in levelsfrom !10 copies/10 5 PBMC (case subjects 5 and 15) to 11000 copies/10 5 PBMC (case subject 2). However, when we examined the time sequential change in HTLV-I proviral DNA load over several years, there was no obvious trend during the observa- peripheral blood mononuclear cells. Primers for HTLV-I gag and pol regions were used for quantitative assessment of HTLV-I proviral DNA load by AmpliSensor assay. Primers for HTLV-I pX were used for nested polymerase chain reaction (PCR) assay. Blank space indicates missing information due to nonattendance at annual health examination or because of insufficient volume of sample for testing. There were no data for Y8. N, negative for the nested PCR assay; P, positive for the nested PCR assay; Y, year.
a Year of screens before and after seroconversion; year of last seronegative sample is reference year (Y0).
tion period, and HTLV-I proviral DNA loads in each case subject were fairly stable. DNA samples from PBMC collected before and after seroconversion were available for 8 case subjects (table 3; case subjects 1, 2, 5, 9, 14, 15, 19, and 22). Representative results (case subject 19) for detection of HTLV-I by using nested PCR with primers for the HTLV-I pX sequence before and after seroconversion are shown in figure 1B. At the 2 screens before seroconversion, no HTLV-I pX sequence was detected; however, this sequence was found consistently for 4 years after seroconversion. One case subject (case subject 15) showed no detectable anti-HTLV-I for 7 years by PAA and immunoblot assay ( figure  2A) . The first sample that tested positive for anti-HTLV-I by PAA exhibited reactivity mainly to HTLV-I p19 and very weak Figure 2 . Time-sequential analysis of anti-human T lymphotropic virus type I (HTLV-I) response and presence of HTLV-I DNA from seroconverter (case subject 15) with antibody-negative but HTLV-I DNA-positive period before seroconversion. Nos. at top of panels indicate year of sample collection (year 0, reference year for last seronegative sample). A, Immunoblot analysis of anti-HTLV-I for samples from different screens before and after seroconversion. N, negative control sample from test kit; P, positive control sample from test kit that showed reactivity to HTLV-I core proteins (p53, p24, and p19) and envelope protein (gp46). B, Detection of HTLV-I pX sequence in genomic DNA from peripheral blood mononuclear cells, using nested polymerase chain reaction. N, negative control genomic DNA from MOLT-4 cells; P, positive control genomic DNA from HuT 102 cells.
reactivities to p24 and p53. Samples from subsequent screens showed an increased reactivity to both HTLV-I core and envelope proteins (gp46); however, those reactivities were much weaker than seen for other case subjects (e.g., case subject 19; figure 1B ). Of note, the sample collected from this case subject 1 year before anti-HTLV-I seroconversion tested positive for HTLV-I pX sequence (table 3; figure 2B ). In addition, the HTLV-I proviral DNA load measured with the primer for HTLV-I pol sequence was 780 copies/10 5 PBMC in the same year. The HTLV-I proviral DNA load decreased to !10 copies/ 10 5 PBMC in subsequent years when anti-HTLV-I became positive (table 3) . This case subject's wife was positive for anti-HTLV-I (table 1) . This finding suggests that there is a potential "window" period with HTLV-I infection that is acquired sexually when only HTLV-I proviral DNA loads are detectable in peripheral blood.
Discussion
It is important to know the early events of HTLV-I infection to clarify the natural history of community-acquired infection. However, there have been few relevant reports, and most were based on data from HTLV-I transmission via blood transfusion [18, 19] . The MCS, a unique long-term follow-up study of both HTLV-I-positive and -negative subjects in an area in which HTLV-I is highly endemic, has enabled identification of 23 anti-HTLV-I seroconverters through 11 years of observation. Of the seroconverters, 90% had a spouse who tested positive for anti-HTLV-I. None appeared to have been infected via blood transfusion. Therefore, the seroconversions observed were probably due to a new infection from their sex partner.
Analysis of anti-HTLV-I response in 17 subjects could be done in the initial year of seroconversion, and titers у1:512 were found in 82%. The overall anti-HTLV-I titer and the specific reactivity to the core and envelope proteins increased slightly or did not change during the 2-10 years of observation after seroconversion. Manns et al. [19] reported that anti-HTLV-I titers were low in the early measurements after infection via blood transfusion (1-3 months), and then increased and became stable in later measurements (у7 months later). In the present study, subjects were evaluated annually, and the sequential change in antibody response over time was assessed for a longer period. Alternatively, the level of antibody response may have been affected by the route of infection, which differed in the 2 studies. On the basis of the findings from both studies, antibody production in most seroconverters who acquire HTLV-I infection as adults appears to reach fairly stable levels within a year after seroconversion and may slightly increase over longer periods.
In the present study, the HTLV-I proviral DNA load in the initial year of seroconversion varied from case subject to case subject over a wide range of values. However, time sequential measurements for several years showed fairly stable levels for each seroconverter on the basis of PCR detection of both the gag and pol sequences of HTLV-I. Manns et al. [19] also evaluated changes in HTLV-I proviral DNA load after transfusionacquired infection. They reported that the initial high levels decreased in subsequent measurements. Again, differences in the timing of sample collection may account for the differences between the 2 studies. In fact, for the 1 seroconverter in the present study whose initial measurement was assumed to have been made soon after infection (case subject 15), the HTLV-I proviral DNA load was moderately high at the initial measurement (780 copies/10 5 PBMC) but decreased in the following year (!10 copies/10 5 PBMC). A wide range in HTLV-I proviral DNA load was observed among asymptomatic HTLV-I carriers in the present cohort population [16, 20, 21] and in other studies [19, 22, 23] . Stability in HTLV-I proviral DNA load over time also has been found among the asymptomatic carriers in this study population [16] . Thus, the HTLV-I proviral DNA load of an HTLV-I carrier may become stable relatively soon (presumably within a year) after initial infection of an adult.
Among 8 subjects for whom PBMC samples were available before antibody seroconversion, 1 was positive for HTLV-I provirus, as determined by nested PCR. Because the HTLV-I sequence was amplified with primers for 2 different HTLV-I regions (pol and pX), cross-contamination was unlikely. Therefore, this subject was considered to have a detectable HTLV-I DNA proviral load before the development of antibodies. There have been several reports of perinatal infection associated with seronegativity for HTLV-I antibodies [24, 25] . However, other studies have shown an absence of HTLV-I carriers without anti-HTLV-I [26, 27] . To date, no antibody-negative HTLV-I carriers have been identified in the MCS. In the 1 seroconverter who had detectable HTLV-I DNA 1 year before the detection of antibodies, samples from 2 and 3 years before seroconversion tested negative for HTLV-I by nested PCR. Moreover, the sequence of the amplified env region of this subject exactly matched that of his spouse (authors' unpublished data). Therefore, it is much more likely that the initially detected HTLV-I provirus represented the early phase of a new infection from his spouse, before the development of a detectable antibody response, rather than that this subject was originally a seronegative carrier. The presence of such a window period has been seen in the early phase of infection with other viruses (e.g., hepatitis C virus and human immunodeficiency virus) [28] .
Since samples were only collected annually, it is not clear how long the window period continued for this particular HTLV-I seroconverter. It took a few years for the subject to develop antibodies to all the examined HTLV-I core and envelope proteins, and the reactivities were still very weak to some structural proteins (e.g., p24 and gp46), as shown in figure 2A . This pattern of antibody reactivity was not common among the other seroconverters. Therefore, an unusual humoral response may account for the detection of a window period for this seroconverter. The decreased level of expression of these viral proteins, which might be caused by substitutions in the proviral sequence, is another possible explanation for the presence of an antibody-negative, PCR-positive period; however, sequencing of the env region did not show any amino acid substitutions that would change the nature of this protein (data not shown). The presence of a window period can be problematic when blood products are screened by measuring antibody to a pathogen. Screening of blood products for anti-HTLV-I has been done in Japan since 1986 and has been successful in identifying HTLV-I-contaminated units [29] . Further study might be necessary to determine whether a possible window period for HTLV-I infection could affect the methods used to screen blood products.
In conclusion, the longitudinal changes in anti-HTLV-I response and HTLV-I proviral DNA load were assessed after incident adult infection, which was assumed primarily to be sexually transmitted between spouses. The levels of both markers were fairly stable for р10 years after seroconversion. In addition, an anti-HTLV-I-seronegative but PCR-positive window period was found among seroconverters.
